An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1818-1825

  Barnett, Anthony H ^a,e   Dreyer, Manfred ^b   Lange, Peter ^c   Serdarevic Pehar, Marjana ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Krankenhaus Bethanien   (Germany)

^c HVIDOVRE HOSPITAL   (Denmark)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; METFORMIN;

ABDOMINAL PAIN; ABNORMAL VISION; ADD ON THERAPY; ADULT; AGED; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DIABETES CONTROL; DIZZINESS; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SWEATING; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; RANDOM ALLOCATION; TREATMENT OUTCOME;

EID: 33746593639     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc05-1880     Document Type: Article

References (33)

1. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28 (Suppl. 1):S4-S36, 2005
2. European Diabetes Policy Group: Guidelines for diabetes care: a desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
3. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S15-S35, 2004
4. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, the U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
5. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012, 1999
6. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 108:15S-22S, 2000
7. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 27:17-20, 2004
8. Polonsky WH, Jackson RA: What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes 22:147-150, 2004
9. Korytkowski M: When oral agents fail; practical barriers to starting insulin. Int J Obes 26 (Suppl 3):S18-S24, 2002
10. Zambanini A, Newson RB, Maisey M, Feher MD: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Prac 46:239-246, 1999
11. Mollema ED, Snoek FJ, Heine RJ, van ver Ploeg HM: Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 18:671-674, 2001
12. Barnett AH: Exubera inhaled insulin: a review. Int J Clin Pract 58:394-401, 2004
13. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS, the Exubera Phase III Study Group: Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 28:1922-1928, 2005
14. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH, the Inhaled Insulin Phase II Study Group: Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 163:2277-2282, 2003
15. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan S-P, Cefalu WT: Mealtime inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing two oral agents. Annals Intern Med 143:549-558, 2005
16. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson J-L, Levin SR, the Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2356-2362, 2004
17. Franz MJ, Horton ES Sr, Bantle JP, Beebe CA, Brunzell JD, Coulston AM, Henry RR, Hoogwerf BJ, Stacpoole PW: Nutrition principles for the management of diabetes and related complications (Technical Review). Diabetes Care 17:490-518, 1994
18. American Diabetes Association (ADA): Diabetes mellitus and exercise. Diabetes Care 21 (Suppl. 1):40-44, 1998
19. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L, Gelfand RA, the Inhaled Insulin Study Group: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134:203-207, 2001
20. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.NEngl J Med 329:977-986, 1993
21. Agresti A: Categorical Data Analysis. New York, John Wiley & Sons, 1990, p. 165-200
22. Anderson PK, Gill RD: Cox's regression model counting process: a large sample study. Annals of Statistics 10:1100-1120, 1982
23. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, the Exubera Phase III Study Group: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29:1282-1287, 2006
24. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KMV: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 136:565-574, 2002
25. Suwattee R, Lynch JC, Pendergrass ML: Quality of care for diabetic patients in a large urban public hospital. Diabetes Care 26:563-568, 2003
26. Fleming BB, Greenfield S, Engelgan MM, Pogach LM, Clauser SB, Parrott MA: The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care 24:1815-1820, 2001
27. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner C, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321:405-412, 2000
28. Heine RJ: Current therapeutic options in type 2 diabetes. Eur J Clin Invest 29 (Suppl. 2):17-20, 1999
29. Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L: Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 23:1612-1618, 2000
30. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR: Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28:995-1000, 2005
31. Ovalle F, Bell DSH: Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 4:146-147, 1998
32. Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 (Suppl. M):M8-M14, 1998
33. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. J Clin Endocrinol Metab 90:3287-3294, 2005